| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
82,823,000 |
| Market
Cap: |
1.74(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$18.92 - $29.92 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 484 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Veracyte is a genomic diagnostics company. Co. develops tests that address clinical needs in the diagnosis, prognosis and treatment of cancer and other diseases. Co. provides tests in: thyroid cancer via its Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas; prostate cancer via its Decipher Biopsy and Radical Prostatectomy Genomic Classifiers; breast cancer via its Prosigna Breast Cancer Assay; lung cancer via its Percepta GSC and Percepta Nasal Swab Test; interstitial lung diseases including idiopathic pulmonary fibrosis via its Envisia Genomic Classifier; bladder cancer via its Decipher Bladder Genomic Classifier; and colon cancer via its Immunoscore Colon Cancer Test.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
21,779 |
31,779 |
114,409 |
523,205 |
| Total Sell Value |
$459,589 |
$703,188 |
$3,171,383 |
$13,848,977 |
| Total People Sold |
2 |
3 |
4 |
6 |
| Total Sell Transactions |
5 |
6 |
15 |
32 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Anderson Bonnie H |
Chairman and CEO |
• • – |
2021-05-17 |
4 |
OE |
$5.61 |
$78,905 |
D/D |
14,065 |
192,013 |
|
- |
|
| Alley Beverly Jane |
VP, Corporate Controller |
• – – |
2021-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
5,500 |
13,000 |
|
- |
|
| Eastham Karin |
Director |
– • – |
2021-05-03 |
4 |
AS |
$48.01 |
$213,700 |
I/I |
(4,427) |
8,800 |
|
6% |
|
| Bhanji Muna |
Director |
– • – |
2021-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
11,541 |
11,541 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2021-03-04 |
4 |
AS |
$47.11 |
$2,567,271 |
D/D |
(52,015) |
53,724 |
|
-24% |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2021-03-04 |
4 |
OE |
$5.98 |
$582,299 |
D/D |
30,970 |
105,739 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2021-03-02 |
4 |
D |
$62.15 |
$372,589 |
D/D |
(5,995) |
74,769 |
|
- |
|
| Ho Mark |
Principal Accounting Officer |
– – – |
2021-03-02 |
4 |
D |
$62.15 |
$30,454 |
D/D |
(490) |
71,728 |
|
- |
|
| Kennedy Keith |
COO / CFO |
• – – |
2021-03-02 |
4 |
D |
$62.15 |
$359,413 |
D/D |
(5,783) |
116,858 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2021-03-02 |
4 |
D |
$62.15 |
$392,788 |
D/D |
(6,320) |
177,948 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
184,268 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
80,764 |
|
- |
|
| Kennedy Keith |
COO / CFO |
• – – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
122,641 |
|
- |
|
| Erlinger Iii James H |
EVP, General Counsel |
– – – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
7,500 |
|
- |
|
| Eastham Karin |
Director |
– • – |
2021-02-25 |
4 |
AS |
$60.03 |
$379,359 |
D/D |
(6,250) |
0 |
|
-35% |
|
| Eastham Karin |
Director |
– • – |
2021-02-25 |
4 |
OE |
$4.00 |
$25,000 |
D/D |
6,250 |
6,250 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2021-02-24 |
4 |
D |
$62.30 |
$2,460,102 |
D/D |
(39,488) |
164,268 |
|
- |
|
| Kennedy Keith |
COO / CFO |
• – – |
2021-02-24 |
4 |
D |
$62.30 |
$688,166 |
D/D |
(11,046) |
107,641 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2021-02-24 |
4 |
D |
$62.30 |
$625,990 |
D/D |
(10,048) |
68,264 |
|
- |
|
| Jones Evan/ Fa |
Director |
– • – |
2021-01-22 |
4 |
OE |
$2.36 |
$11,800 |
D/D |
5,000 |
30,000 |
|
- |
|
| Ho Mark |
Principal Accounting Officer |
• • – |
2021-01-20 |
4 |
OE |
$4.94 |
$270,675 |
D/D |
52,500 |
71,434 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2021-01-13 |
4 |
AS |
$50.64 |
$946,462 |
D/D |
(18,541) |
203,756 |
|
-23% |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2021-01-13 |
4 |
OE |
$5.61 |
$104,015 |
D/D |
18,541 |
222,297 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2021-01-12 |
4 |
AS |
$49.77 |
$1,021,772 |
D/D |
(20,354) |
203,756 |
|
-24% |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2021-01-12 |
4 |
OE |
$5.61 |
$114,186 |
D/D |
20,354 |
224,110 |
|
- |
|
551 Records found
|
|
Page 8 of 23 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.82 (3.76%) 
